The Leukemia & Lymphoma System is encouraged by this week’s spot from Celgene Corp. that its investigational
dope Revlimid has shown assurance in the treatment of relapsed or refractory myeloma in two insinuate III clinical trials.

Celgene said that an independent board analyzing both shape III multiple myeloma trials indicated that the tests exceeded
expectations. The pharmaceutical company said the committee found a statistically valuable upswing in the time it took
for the malady to worsen in patients receiving Revlimid additional a steroid in compared with patients receiving the steroid and a
placebo.

“We need to review the details of these results, but if Revlimid proves effective in delaying the progress of myeloma then it
intent be an important incremental start in the treatment of a disease that has been altogether resistant to therapy,” said Marshall
Lichtman, M.D., executive degradation president, Research & Medical Programs, The Leukemia & Lymphoma League. “This development
offers promise of extended survival in the service of myeloma patients.”

Celgene has begun discussions with the U.S. Chow and Drug Management and global regulatory authorities regarding
the concession of this data instead of capability uphold. The studies proved so effective that the company halted them untimely to
allow all participating patients access to Revlimid. The trials enrolled 705 patients and were being conducted in 97 sites
internationally.

Revlimid is not approved for the sake clinical use in the United States or anywhere else in the great. Celgene is evaluating
treatments with Revlimid for a broad range of blood and cancer conditions, including multiple myeloma, myelodysplastic
syndromes (MDS) as evidently as solid tumor cancers.

All round Myeloma

Myeloma is a disease that starts in the marrow, the spongy accumulation found in the center of the bone where red and milky blood
cells are made. In myeloma, identical kind of developing white blood cell (B lymphocyte), grows continually to stamp a magnitude, or
tumor, in the marrow. That takes on the appearance of plasma cells.

When there are too many plasma cells, they crowd out developing well-adjusted white and red blood cells. The plasma cells in myeloma
fancy factors that cause bone to fade away, leading to fractures. They also do no deliver antibodies to infectious agents. Fewer
red blood cells result in less oxygen being carried to the network throughout the body, causing lassitude and shortness of
breath with exercise. Fewer white blood cells set upon it harder to set-to infection.

Relating to 90 percent of all myelomas are develop in more than everyone site, including the ribs, backbone, pelvis, thrust aside bones,
breastbone and skull, in which case the most common form is known as multiple myeloma.

Almost 55,000 people in the United States are living with myeloma. More than 15,000 immature cases were diagnosed in the United
States in 2004. The median age at diagnosis is 71 years of age and it scarcely ever occurs in people subordinate to life-span 50. Americans of
African descent give birth to a much higher rate rate (11.9/100,000) of myeloma than those of European descent (5.3/100,000).

Chemotherapy on account of myeloma has led to sustained remissions in some patients. At times, two or three drugs are used
simultaneously. Velcade(reg) has been approved conducive to treating myeloma in patients that suffer with had at least two last therapies.
Thalidomide and its derivatives eat been added to the drugs and found to be unusually useful in the treatment of the disease.
Treatment may encompass intensive chemotherapy followed by stanch cell transplantation to restore regular blood chamber direction.
Chiefly, the patient’s own arise cells are used.

For more information, readers should fall upon the Society’s Trap locale, http://www.lls.org/myelomaeducation , to find out out close to upcoming and archived lesson programs. These
programs are offered at no charge. Further details of treatment and sympathetic supervision look after and the favourable and adverse effects of
treatment may be obtained from the Society’s word booklet Myeloma.

About The Leukemia & Lymphoma Fraternity

The Leukemia & Lymphoma Society, headquartered in White Plains, NY, with 63 chapters in the Connected States and additional
branches in Canada, is the world’s largest intentional health order dedicated to funding blood cancer research and
providing schooling and long-suffering services. The Society’s mission: Therapy leukemia, lymphoma, Hodgkin’s disease and myeloma, and
promote the quality of life of patients and their families. Since its founding in 1949, the Society has invested more than
$360 million in check in specifically targeting leukemia, lymphoma and myeloma. Last year unique, the Society made more than
812,000 contacts with patients, caregivers and healthcare professionals.

For more data about blood cancer, visit http://www.LLS.org or call
the Society’s Information Resource Center (IRC), a call center staffed by master’s level social workers, nurses and health
educators who provide information, support and resources to patients and their families and caregivers. IRC information
specialists are close by at (800) 955-4572, Monday as a consequence Friday, 9 a.m. to 6 p.m. ET.

Friend: Andrea Greif, (914) 821-8958
This is a embrace unloosing from the Leukemia & Lymphoma Elite

Consider drug information on Revlimid; Velcade.